Security key
98422T100
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)
CUSIP: 98422T100
Q3 2023 13F Holders as of 30 Sep 2023
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 6,426,426
- Total 13F shares
- 15,860,160
- Share change
- -140,549
- Total reported value
- $33,465,952
- Price per share
- $2.11
- Number of holders
- 30
- Value change
- -$314,935
- Number of buys
- 7
- Number of sells
- 9
Report period
Q3 2023
Institutions
30
Top holders
10
XLO full security history
Newer quarter: Q4 2023
Previous quarter: Q2 2023
Xilio Therapeutics, Inc. SEC filings
Xilio Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98422T100
Recent filing periods:
Top shareholders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
|
Company · 10%+ Owner |
44%
|
2,805,413
|
$7,350,182 | — | 30 Jun 2023 | |
| Atlas Venture Life Science Advisors, LLC |
13F
|
Company |
43%
|
2,759,344
|
$7,229,481 | — | 30 Jun 2023 | |
| Octagon Capital Advisors LP |
13F
|
Company |
38%
|
2,425,000
|
$6,353,500 | — | 30 Jun 2023 | |
| FMR LLC |
13F
3/4/5
|
Company · Other* |
30%
|
1,907,671
|
$4,998,098 | — | 30 Jun 2023 | |
| RiverVest Venture Management LLC |
13F
|
Company |
22%
|
1,441,444
|
$3,776,583 | — | 30 Jun 2023 | |
| Rock Springs Capital Management LP |
13F
3/4/5
|
Company · 10%+ Owner |
22%
|
1,440,759
|
$3,774,789 | — | 30 Jun 2023 | |
| SV7 Impact Medicine Fund LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,227,264
|
$2,678,630 | — | 26 Oct 2021 | |
| VANGUARD GROUP INC |
13F
|
Company |
14%
|
890,353
|
$2,332,725 | — | 30 Jun 2023 | |
| James E. Flynn |
3/4/5
|
Possible Member of 10% Group, 10%+ Owner |
—
class O/S missing
|
2,287,944
|
$1,898,994 | — | 26 Oct 2021 | |
| TAKEDA PHARMACEUTICAL CO LTD |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,475,121
|
$1,224,350 | — | 26 Oct 2021 | |
| RiverVest Venture Fund IV, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,441,444
|
$1,196,399 | — | 26 Oct 2021 | |
| Artal Group S.A. |
13F
|
Company |
7%
|
450,000
|
$1,179,000 | — | 30 Jun 2023 | |
| HARVARD MANAGEMENT CO INC |
13F
|
Company |
6.5%
|
416,059
|
$1,090,000 | — | 30 Jun 2023 | |
| BAY CITY CAPITAL LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,129,490
|
$937,477 | — | 26 Oct 2021 | |
| Trustees of Columbia University in the City of New York |
13F
|
Company |
3.9%
|
249,635
|
$654,044 | — | 30 Jun 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
3.5%
|
227,207
|
$595,283 | — | 30 Jun 2023 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
3.5%
|
226,941
|
$594,585 | — | 30 Jun 2023 | |
| FIL Ltd |
13F
3/4/5
|
Company · Other* |
3.4%
|
218,705
|
$573,007 | — | 30 Jun 2023 | |
| Merck KGaA |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
680,825
|
$565,085 | — | 26 Oct 2021 | |
| Laurion Capital Management LP |
13F
|
Company |
2.2%
|
142,900
|
$374,398 | — | 30 Jun 2023 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
110,481
|
$289,460 | — | 30 Jun 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
84,726
|
$221,982 | — | 30 Jun 2023 | |
| Alexandria Venture Investments, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
166,423
|
$138,131 | — | 26 Oct 2021 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.77%
|
49,211
|
$128,933 | — | 30 Jun 2023 | |
| Simon M. Tomlinson |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
131,117
|
$108,827 | — | 21 Oct 2021 | |
| John Charles Williams |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
100,080
|
$83,066 | — | 21 Oct 2021 | |
| Of Ulrich Rodeck Estate |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
100,080
|
$83,066 | — | 21 Oct 2021 | |
| Timothy P. Clackson |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
90,956
|
$75,493 | — | 21 Oct 2021 | |
| MORGAN STANLEY |
13F
|
Company |
0.42%
|
27,016
|
$70,782 | — | 30 Jun 2023 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.32%
|
20,300
|
$53,000 | — | 30 Jun 2023 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.28%
|
17,881
|
$46,848 | — | 30 Jun 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.28%
|
17,798
|
$46,631 | — | 30 Jun 2023 | |
| STATE STREET CORP |
13F
|
Company |
0.24%
|
15,690
|
$41,108 | — | 30 Jun 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.2%
|
13,149
|
$34,450 | — | 30 Jun 2023 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.2%
|
12,894
|
$33,782 | — | 30 Jun 2023 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.19%
|
11,925
|
$31,244 | — | 30 Jun 2023 | |
| NWAM LLC |
13F
|
Company |
0.16%
|
10,000
|
$26,200 | — | 30 Jun 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.07%
|
4,394
|
$11,512 | — | 30 Jun 2023 | |
| Rachel Humphrey |
3/4/5
|
Director |
—
class O/S missing
|
9,444
|
$7,839 | — | 21 Oct 2021 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.04%
|
2,701
|
$7,077 | — | 30 Jun 2023 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.02%
|
1,577
|
$4,000 | — | 30 Jun 2023 | |
| Key FInancial Inc |
13F
|
Company |
0.01%
|
830
|
$2,175 | — | 30 Jun 2023 | |
| UBS Group AG |
13F
|
Company |
0%
|
201
|
$527 | — | 30 Jun 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
81
|
$212 | — | 30 Jun 2023 | |
| Martin H. Huber Jr. |
3/4/5
|
PRESIDENT AND HEAD OF R&D |
—
class O/S missing
|
136,500
|
— | — | 16 Aug 2023 | |
| Salvatore Giovine |
3/4/5
|
CHIEF FINANCIAL OFFICER |
—
class O/S missing
|
49,500
|
— | — | 22 Feb 2022 | |
| Edward C. English |
3/4/5
|
PRINCIPAL ACCOUNTING OFFICER |
—
class O/S missing
|
24,000
|
— | — | 01 Jan 2023 | |
| Michael Jay Ross |
3/4/5
|
Director |
—
class O/S missing
|
13,200
|
— | — | 15 Jun 2022 | |
| Tomas J. Heyman |
3/4/5
|
Director |
—
class O/S missing
|
13,200
|
— | — | 12 Jun 2023 |
Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q3 2023
As of 30 Sep 2023,
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,860,160 shares.
The largest 10 holders included
Bain Capital Life Sciences Investors, LLC, Atlas Venture Life Science Advisors, LLC, Octagon Capital Advisors LP, FMR LLC, RiverVest Venture Management LLC, Rock Springs Capital Management LP, VANGUARD GROUP INC, Artal Group S.A., HARVARD MANAGEMENT CO INC, and Trustees of Columbia University in the City of New York.
This page lists
30
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2023 vs Q2 2023 Across Filers
Q2 2023 holders
32
Q3 2023 holders
30
Holder diff
-2
| Investor | Q2 2023 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q2 2023 Value $ | Q3 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.